Schizophrenia drugs linked to increased risk of heart attack

November 07, 2002

(Philadelphia, PA) - Schizophrenic patients who take antipsychotic drugs are more likely to have experienced cardiac arrest or ventricular arrhythmia than non-schizophrenic patients, according to researchers at the University of Pennsylvania School of Medicine. While previous research has linked several of these drugs to irregular electrocardiogram results, the Penn researchers used billing data to uncover a link between the drugs and cardiac arrest. Their findings are presented in the November 9 issue of the British Medical Journal.

The study's primary comparison was between thioridazine, which has a marked effect on the electrocardiogram, and haloperidol, which has less of an effect. "Overall, the risk with thioridazine was no worse than that with haloperidol. Thioridazine may, however, represent an elevated risk at high doses," said Sean Hennessy, PharmD, PhD, assistant professor in Penn's Department of Biostatistics and Epidemiology. "To reduce cardiac risk, thioridazine should be prescribed at the lowest dose needed to obtain an optimal therapeutic effect."

Hennessy and his colleagues conducted a cohort study of billing data collected between 1993 and 1996 from three Medicaid programs. The researchers included patients with more than one prescription for oral thioridazine and haloperidol, as well as the antipsychotic drugs risperidone and clozapine, plus at least two instances of a schizophrenia diagnosis. They compared the records of these patients with two control groups - one group of glaucoma patients and one group of psoriasis patients - since both patient types require periodic prescriptions and are not associated with cardiovascular problems. In all, they looked at data taken from over 120,000 patients.

"We compared the frequency of cardiac arrest and ventricular arrhythmia associated with different antipsychotic drugs versus the control groups," said Hennessy. "Our findings clearly link patients with treated schizophrenia to higher rates of cardiac arrest, ventricular arrhythmia, and death." According to Hennessy, the elevated risk could be a result of either the disease or its treatment. While haloperidol and thioridazine both presented a similar overall risk in this study, the effect with thioridazine seemed to be dose-related. "Therefore, to minimize the risk of arrhythmia, it seems prudent to suggest that physicians prescribe the lowest dose of thioridazine possible," said Hennessy.

Separate data presented to FDA have suggested that thioridazine may have a greater effect than haloperidol on the QT interval as recorded on an electrocardiogram (ECG). The QT interval is defined as the time between the Q wave (when the heart's ventricles contract) and T wave (when the ventricles relax again). While QT prolongation is often used as a surrogate marker of a drug's cardiac risk, the true relationship is unknown. This study helps to clarify that relationship.

"If our findings are confirmed, they would support the use of QT prolongation as a marker for a drug's risk," said Hennessy, "There are still plenty of questions to be asked. Is there a certain subset of the population more at risk for developing a QT irregularity with certain drugs? Is there a role for regular ECG monitoring in individual patients? Obviously, we shouldn't be keeping QT on the Q.T."
-end-


University of Pennsylvania School of Medicine

Related Cardiac Arrest Articles from Brightsurf:

Outcomes for out-of-hospital cardiac arrest during COVID-19 pandemic
This study used a large US registry of out-of-hospital cardiac arrests to asses the association between the COVID-19 pandemic and the outcomes of out-of-hospital cardiac arrests, including in areas with low and moderate COVID-19 disease.

Cardiac arrest is common in critically ill patients with COVID-19
Cardiac arrest is common in critically ill patients with covid-19 and is associated with poor survival, particularly among patients aged 80 or older, finds a study published by The BMJ today.

In-hospital cardiac arrest in COVID-19
Outcomes of in-hospital cardiac arrest among patients with COVID-19 are examined in this case series.

New risk tool developed for cardiac arrest patients
Experts have developed a risk score to predict cardiac arrest patient outcomes.

Intravenous sodium nitrite ineffective for out-of-hospital cardiac arrest
Among patients who had an out-of-hospital cardiac arrest, intravenous sodium nitrite given by paramedics during resuscitation did not significantly improve their chances of being admitted to or discharged from the hospital alive, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Getting to the heart of epinephrine use in pediatric cardiac arrest patients
The effectiveness of epinephrine treatment during resuscitation of adult patients with cardiac arrest is generally promising, but little is known about its effects in pediatric patients.

Bystanders can help more cardiac arrest victims survive
Only 8% of Americans survive cardiac arrest outside a hospital, but that percentage could increase significantly if bystanders recognize cardiac arrest and perform simple lifesaving tasks, a UVA Health physician says in a New England Journal of Medicine article.

Opioid-related cardiac arrest patients differ from other cardiac arrests
People who suffer cardiac arrest due to an opioid overdose are younger, have fewer chronic medical conditions and may be more likely to be to receive bystander CPR, according to a review of emergency response records in Maine.

Selective coronary angiography following cardiac arrest
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Sudden cardiac arrest in athletes: Prevention and management
It's marathon season, and every so often a news report will focus on an athlete who has collapsed from sudden cardiac arrest.

Read More: Cardiac Arrest News and Cardiac Arrest Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.